SCHEMBL10135601

SCHEMBL10135601

Brc1c(CN2CCCNCC2)ccc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 10/20 0.48
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
MEN1 O00255 1/20 0.47
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
ADRA2C P18825 1/20 0.47
CCR2 P41597 1/20 0.47
CXCL12 P48061 1/20 0.47
BLM P54132 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
LMNA P02545 2/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 2/20 0.43
MAPT P10636 2/20 0.43
SIGMAR1 Q99720 1/20 0.43
GABRA1 P14867 1/20 0.42
GABRB2 P47870 1/20 0.42
CRHBP P24387 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL673928 0.80 CXCR4 (0.63) CXCR4KMT2ATDP1MEN1CHRM2
Bromide SCHEMBL1259395 0.77 CXCR4 (0.60) CXCR4KMT2ATDP1MEN1CHRM2
SCHEMBL1020430 0.76 ACHE (0.62) LMNAKDM4EALDH1A1SIGMAR1HTR6
SCHEMBL16689990 0.76 ACHE (0.62) LMNAKDM4EALDH1A1SIGMAR1HTR6
SCHEMBL29567963 0.76 ACHE (0.62) LMNAKDM4EALDH1A1SIGMAR1HTR6
Bromide SCHEMBL9067059 0.75 ACHE (0.60) LMNAKDM4EALDH1A1SIGMAR1HTR6
SCHEMBL16830451 0.75 ACHE (0.60) CXCR4LMNAKDM4EALDH1A1SIGMAR1
SCHEMBL16830450 0.75 KDM4E (0.59) CXCR4KMT2ATDP1MEN1CHRM2
SCHEMBL17929339 0.74 CXCR4 (0.58) CXCR4KMT2ATDP1MEN1CHRM2
SCHEMBL947433 0.72 LMNA (0.76) LMNAKDM4EALDH1A1GAAHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8951997-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2015-02-10 US disclosed
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE SULT1A1, SULT1E1, SULT2A1 CXCR4 498/4885KMT2A 1007/4885TDP1 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.